-
Mashup Score: 1
Transfusion of red blood cells (RBCs) can be lifesaving for individuals living with sickle cell disease (SCD). However, alloimmunization following transfus
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 31
Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional infusions of CAR-T cells with different targets. However, critical challenges, including graft-versus-host disease and CAR-T cell elimination by the host immune system, still require extensive research. The most common technological approaches involve modifying healthy donor T cells via gene editing technology and altering different types of T cells. This article summarizes some of the latest data from preclinical and clinical studies of off-the-shelf CAR-T cell therapies in the treatment of R/R B-cell malignancies from the 2023 ASH Annual Meeting (ASH 2023).
Source: jhoonline.biomedcentral.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity - 3 day(s) ago
CAR T cells display distinctive profiles and actions in patients with CNS autoimmunity.
Source: www.science.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 25Defining Primary Refractory Large B-cell Lymphoma - 9 day(s) ago
Key Points. Patients with SD/PD to 1L therapy have lower RRs to 2L therapy and poor outcomes compared to other subgroups of primary refractory diseaseWe ad
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 25Defining Primary Refractory Large B-cell Lymphoma - 9 day(s) ago
Key Points. Patients with SD/PD to 1L therapy have lower RRs to 2L therapy and poor outcomes compared to other subgroups of primary refractory diseaseWe ad
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 21Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim - 9 day(s) ago
Key Points. This was a prospective long term follow-up study including 14530 PBSC and 7123 BM volunteer unrelated donors from the NMDP.PBSC and BM donors h
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20Risk of T-cell Malignancy Following CAR T cells in Children, Adolescents and Young Adults - 9 day(s) ago
Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon L.
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 24Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality - 10 day(s) ago
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10
PURPOSE Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a three-arm randomized control trial (Blood and Marrow Transplants Clinical Trials Network 0702 Stem Cell Transplant for Myeloma in Combination of Novel Agents [STaMINA]; ClinicalTrials.gov identifier: NCT01109004). METHODS Four hundred and thirty-five patients consented to the MRD panel, which included 10 monoclonal antibodies measured via six-color MFC. MRD was measured at baseline/preautologous hematopoietic cell transplant (BL/preAutoHCT), premaintenance (PM), and 1 year (Y1) after AutoHCT with a sensitivity of 10–5 to 10–6. The primary objective was to assess MRD-negative (MRDneg) at 1 year after AutoHCT and progression-free survival and overall survival (PFS/OS). RESULTS Similar to the STaMINA results, at a median follow-up of 70 months, there was
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention - 11 day(s) ago
Key Points. High-dose alemtuzumab led to effective suppression of chronic GVHD.Lymphodepletion delays Tn recovery resulting in lower TCR repertoire and hig
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
How I Treat Challenging Transfusion Cases in Sickle Cell Disease https://t.co/2nwT3kGKa8